Design
Review
Authors
Loading...
Does not alter current RAS inhibitor use; leaves open targeted nonclassical pathway trials for hypertension and CKD.
Key points are not available for this paper at this time.
Mark C. Chappell (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: